《柳叶刀》公布RTS,S/AS01疟疾疫苗临床试验结果

The first malaria¹ vaccine² candidate (RTS,S/AS01) to reach phase 3 clinical testing is partially³ effective against clinical disease in young African children up to 4 years after vaccination⁴, according to final trial data, published in The Lancet. The results suggest that the vaccine could prevent a substantial number of cases of clinical malaria, especially in areas of high transmission. The findings reveal that vaccine efficacy against clinical and severe malaria was better in children than in young infants, but waned⁵ over time in both groups. However, protection was prolonged by a booster dose, increasing the average number of cases prevented in both children and young infants.

 

Brian Greenwood, corresponding author and Professor of Clinical Tropical Medicine at London School of Hygiene⁶ & Tropical Medicine in the UK explains, "Despite the falling efficacy over time, there is still a clear benefit from RTS,S/AS01. An average 1363 cases of clinical malaria were prevented over 4 years of follow-up for every 1000 children vaccinated⁷, and 1774 cases in those who also received a booster shot. Over 3 years of follow-up, an average 558 cases were averted⁸ for every 1000 infants vaccinated, and 983 cases in those also given a booster dose."

 

"Given that there were an estimated 198 million malaria cases in 2013, this level of efficacy potentially translates into millions of cases of malaria in children being prevented."

 

The RTS,S/AS01 vaccine was developed for use in sub-Saharan Africa where malaria still kills around 1300 children every day. There is currently no licensed⁹ vaccine against malaria anywhere in the world.

 

The phase 3 randomised trial enrolled¹⁰ 15459 young infants (aged 6 to 12 weeks at first vaccination) and children (5 to 17 months at first vaccination) from 11 sites across seven sub-Saharan African countries (Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique and United Republic of Tanzania) with varying levels of malaria transmission. In 2014, initial phase 3 results at 18 months showed vaccine efficacy of about 46% against clinical malaria in children and around 27% among young infants.

 

In this study, members of the RTS,S Clinical Trials Partnership¹¹ followed up the infants and children for a further 20 to 30 months, respectively, and assessed the impact of a fourth booster dose. Participants were each vaccinated three times with RTS,S/AS01 with or without a booster dose 18 months later, or given four doses of a comparator vaccine (control group).

分享到：